Newswise — Lawrenceville, NJ, USA—October 1, 2018—ISPOR, the professional society for health economics and outcomes research (HEOR), announced that it has published a new Global Healthcare Systems Road Map—Egypt Pharmaceuticals.
ISPOR Global Healthcare Systems Road Maps provide an overview of country-specific, healthcare delivery systems. The Road Maps focus on reimbursement and pricing approval processes by country in one of 3 segments—pharmaceutical, medical devices, or diagnostics. The Society’s “Road Maps” can benefit a variety of stakeholders—such as healthcare decision makers, payers, researchers, industry, clinicians, academicians, and students—who are interested in how a given country reimburses and approves pricing for healthcare technologies. ISPOR Global Health Care Systems Road Maps are validated by country-specific healthcare experts and are updated over time to reflect changes in the country’s healthcare delivery system.
With 100 million citizens, the Arab Republic of Egypt is the most populous country in the Arab world and the third most populous in Africa, according to the 2017 census. Egypt has one of the largest healthcare markets in the Middle East and North Africa. The newly published ISPOR Global Healthcare Systems Road Map—Egypt Pharmaceuticals, reports that universal healthcare coverage, a sustainable development goals for 2030 in the country, will be implemented in stages. The first phase will start in late 2018 and will cover the population of 5 governorates in Egypt—Port Said, Suez, Ismailia, North Sinai, and South Sinai. Coverage will gradually expand to include the entire population by 2032. Currently, approximately 43% of Egypt’s population is without health insurance coverage.
In their 2016/2017 fiscal year budget, Egypt allocated 53.3 billion Egyptian pounds to healthcare spending, which represents 5.7% of total government spending, or 1.6% of gross domestic product (GDP), far below the recommended 3% of GDP as per the Constitution. The World Health Organization’s data on current health expenditure (CHE) as percentage of GDP indicated that CHE was 4.2% of GDP in 2015.
The Global Healthcare Systems Road Map—Egypt Pharmaceuticals is freely available here. Additional information on Egypt can be found in ISPOR’s Pharmacoeconomic Guidelines Around the World—Egypt. Additional information on universal healthcare can be found in ISPOR’s 2018 Top 10 HEOR Trends report. All of the Society’s HEOR tools and resources can be found here.
ISPOR, the professional society for health economics and outcomes research (HEOR), is an international, multistakeholder, nonprofit dedicated to advancing HEOR excellence to improve decision making for health globally. The Society is the leading source for scientific conferences, peer-reviewed and MEDLINE®-indexed publications, good practices guidance, education, collaboration, and tools/resources in the field.
Web: www.ispor.org | LinkedIn: http://bit.ly/ISPOR-LIn | Twitter: www.twitter.com/ISPORorg (@ISPORorg) | YouTube: www.youtube.com/user/ISPORorg/videos | Facebook: www.facebook.com/ISPORorg | Instagram: www.instagram.com/ISPORorg